News/ News/ R&D Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema Phil Taylor amlitelimab, atopic dermatitis, dermatology, Kymab, OX40, Sanofi 0 Comment Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category Share X Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema https://pharmaphorum.com/news/key-drug-in-sanofis-1-45bn-kymab-buyout-shows-promise-in-eczema/
amlitelimab, atopic dermatitis, dermatology, Kymab, OX40, Sanofi
0 Comment
